Compared side by side

Tirzepatide vs eloralintide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

They act on different hormones: tirzepatide activates the GLP-1 and GIP receptors, and eloralintide is a selective agonist of the amylin receptor, the receptor for the fullness hormone the pancreas releases with insulin. Tirzepatide is FDA-approved, as Mounjaro and Zepbound; eloralintide, from Eli Lilly, has been in phase 3 since late 2025 and isn’t approved anywhere. Both are weekly shots, and in their own trials tirzepatide’s 15 mg produced up to 22.5% weight loss at 72 weeks (SURMOUNT-1), and eloralintide’s 9 mg about 20% at 48 weeks in phase 2.

Side by side

ComparedTirzepatideEloralintide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asMounjaro, Zepbound, LY3298176LY3841136, Elora
What it isThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).A once-weekly amylin drug from Eli Lilly, built to copy the fullness hormone the pancreas releases with insulin, and to act on its receptor more selectively than cagrilintide does.
How it worksDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.Once-weekly, long-acting agonist of the amylin receptor, the receptor for amylin, the fullness hormone the pancreas releases with insulin. Unlike cagrilintide, it is selective: it acts far more on amylin receptors than on the calcitonin receptor, a difference Lilly thinks may make it easier on the stomach. The idea is fewer calories through earlier fullness after meals rather than through the GLP-1 pathway. Its half-life of about 14 days keeps blood levels nearly flat across the week. Investigational, from Eli Lilly, in phase 3 since late 2025.
Commonly reportedVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).In trials, fewer cravings, especially for sugar, and less food noise, with nausea and tiredness more likely on the higher doses. It is in phase 3 and not approved anywhere.
Studied rangeFDA label: 2.5–15 mg, starting dose 2.5 mg.Research range: 1–9 mg, starting dose 3 mg. Studied in research — not a recommendation.
How oftenWeeklyWeekly
Half-life~5 days (FDA label)~14 days (measured in people: phase 1 trials, Bhattachar 2026)
RouteSubQ injectionSubQ injection
Typical runFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.Used continuously, once weekly, in its trials: 12 weeks in phase 1 and 48 weeks in phase 2; phase 3 runs about 75 weeks. No trial has tested stopping it.
EvidenceEstablished: clinical trials or FDA-approved use existsModerate: animal studies + some human data
Common side effectsNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigueNausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide or eloralintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Tirzepatide

  • Day 1–28 · 2.5 mg Getting your gut acclimated
  • Day 29–56 · 5 mg First therapeutic dose — weight drops
  • Day 57–112 · 7.5 mg Dual agonism in full effect
  • Day 113–168 · 12.5 mg Max titration reached
  • Day 169–504 Weeks 24 to 72: where most people plateau
  • Day 365+ A maintenance medication, not a course

Every card for tirzepatide, with its sources

Eloralintide

  • Day 1–28 · 3 mg Fullness first, gently
  • Day 29–56 · 6 mg The step where nausea shows up
  • Day 57–336 · 6 mg Holding at 6 mg
  • Day 57–336 · 9 mg The top dose tested
  • Day 85–336 Fewer cravings, quieter food noise
  • Day 337+ A long-term medicine, not a course

Every card for eloralintide, with its sources

Together or one or the other

Tirzepatide and eloralintide are a common stack: eloralintide lists tirzepatide among its common stacks.

RCT · Eloralintide

Eloralintide with tirzepatide

Lilly is testing the two together as EloraTZP, amylin plus GIP and GLP-1. In a 48-week trial in type 2 diabetes, the top pair averaged about 23% weight loss vs about 15% on tirzepatide alone. Side effects were more common in the pairs, mostly while doses were stepping up.

Questions people ask

How long do tirzepatide and eloralintide last?

The half-life of tirzepatide is ~5 days (FDA label). The half-life of eloralintide is ~14 days (measured in people: phase 1 trials, Bhattachar 2026).

How often are tirzepatide and eloralintide taken?

Tirzepatide: weekly. Route: SubQ injection. Eloralintide: weekly. Route: SubQ injection.

How are tirzepatide and eloralintide dosed in research?

The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The research range for eloralintide is 1–9 mg, with a 3 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of tirzepatide and eloralintide?

For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For eloralintide: nausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction.

Are tirzepatide and eloralintide taken together?

Tirzepatide and eloralintide are a common stack: eloralintide lists tirzepatide among its common stacks. Lilly is testing the two together as EloraTZP, amylin plus GIP and GLP-1. In a 48-week trial in type 2 diabetes, the top pair averaged about 23% weight loss vs about 15% on tirzepatide alone. Side effects were more common in the pairs, mostly while doses were stepping up.

Each one in full

Track it in the app

PepVault for iPhone

Taking tirzepatide or eloralintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo